Pharmacokinetic Study and Limited Sampling Strategy of Cyclosporine in Japanese Heart Transplant Recipients
Authors:
Open Access
- 1 January 2006
- journal article
- clinical trial
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 70 (10) , 1307-1311
Abstract
Background The purpose of this study was to characterize the pharmacokinetics of cyclosporine (CsA) in Japanese heart transplant patients, and to optimise the monitoring strategy based on measurements of the area under the curve of plasma concentration absorption phase or 2 h post-dose concentrations (C2). Methods and Results At defined time periods during the first year after transplantation, the area under the curve for the CsA serum concentration from 0 to 4 h (AUC0-4 h) was evaluated. Pharmacokinetic parameters and renal function at 1 month and 12 months after transplantation were compared in 7 Japanese patients. The highest coefficient of determination between CsA AUC0-4 h and a single concentration was observed using C2 (r 2 =0.838). For CsA pharmacokinetics, the mean measurement of whole blood trough levels value at 12 months was significantly lower than at 1 month after transplantation (p=0.026). The mean serum creatinine level at 12 months was significantly higher than at 1 month (1.00 mg/dl vs 0.73 p=0.0194). Conclusion A single-time-point model that includes C2 is useful for predicting CsA AUC0-4 h in Japanese heart transplant patients. Mean C2 values >1,000 ng/ml were obtained in patients with no rejection at 1 month and 12 months after transplantation; however, renal impairment may occur. (Circ J 2006; 70: 1307 - 1311)Keywords
This publication has 19 references indexed in Scilit:
- Monitoring of Cyclosporine 2-Hour Post-Dose Levels in Heart Transplantation: Improvement in Clinical OutcomesThe Journal of Heart and Lung Transplantation, 2005
- Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in TaiwanTransplantation Proceedings, 2004
- Impact of cyclosporine 2‐h level and mycophenolate mofetil dose on clinical outcomes inde novoheart transplant patients receiving anti‐thymocyte globulin inductionClinical Transplantation, 2003
- New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprineClinical Biochemistry, 2001
- Noeral C-2 monitoring in cardiac transplant patientsTransplantation Proceedings, 2001
- Impact of Absorption Profiling on Efficacy and Safety of Cyclosporin Therapy in Transplant RecipientsClinical Pharmacokinetics, 2000
- Neoral absorption profiling: an evolution in effectivenessTransplantation Proceedings, 2000
- CLINICAL BENEFIT OF NEORAL DOSE MONITORING WITH CYCLOSPORINE 2-HR POST-DOSE LEVELS COMPARED WITH TROUGH LEVELS IN STABLE HEART TRANSPLANT PATIENTS1Transplantation, 1999
- NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVETransplantation, 1999
- Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible.Journal of Clinical Investigation, 1995